Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Penpulimab + Cetuximab in R/M SCCHN
NCT05260671Phase 2Recruiting
- Sponsor
- Eye and ENT Hospital of Fudan University
- Start
- Jan 2022
- Primary completion
- Dec 2024
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of penpulimab in squamous cell carcinoma of the head and neck (HNSCC), sponsored by Eye and ENT Hospital of Fudan University. Primary endpoint: Objective Response Rate at 2 years. Started Jan 2022; status: recruiting.
02
Drugs
penpulimab
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT05260671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05260671.